/
IBRX
$8.72+$0.01 (+0.17%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$9.1B
1,047M shares
52-week range
$1.95 – $12.43
65% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
3.23%
Moderate
Price (6 mo)
Loading chart…
Change$-5.56
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.0K | $43.0K | $605.0K | $934.0K | $240.0K | $622.0K | $14.7M | $113.3M |
| Cost of revenue | −$3.1M | $9.0M | $0 | $0 | $0 | $0 | $0 | $753.0K |
| Gross profit | $3.2M | −$9.0M | $605.0K | $934.0K | $240.0K | $622.0K | $14.7M | $112.5M |
| Gross margin | 6717.0% | -20858.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.3% |
| R&D | $53.4M | $48.9M | $139.5M | $196.0M | $248.1M | $232.4M | $190.1M | $207.9M |
| Operating income | −$98.4M | −$66.9M | −$220.9M | −$330.3M | −$351.3M | −$362.3M | −$344.2M | −$256.0M |
| EBITDA | −$86.7M | −$56.9M | −$204.2M | −$320.8M | −$351.9M | −$478.7M | −$264.4M | −$223.6M |
| Net income | −$96.2M | −$65.8M | −$221.9M | −$346.8M | −$416.6M | −$583.2M | −$413.6M | −$351.4M |
| Net margin | -204736.2% | -152997.7% | -36669.6% | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% |
| EPS (diluted) | -0.30 | -0.42 | -0.59 | -0.89 | -1.04 | -1.15 | -0.62 | -0.38 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $222M | $-0.85 | $-0.88–$-0.81 | 2 |
| 2027 | $452M | $-0.16 | $-0.38–$0.07 | 2 |
| 2028 | $1.4B | $0.54 | $0.31–$0.84 | 1 |
| 2029 | $2.3B | $0.95 | $0.55–$1.47 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
ImmunityBio, Inc. Common Stock
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
www.immunitybio.com- Employees
- 691
- IPO / List date
- Mar 10, 2021
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds IBRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 1,231,770 | $2.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IBRX yet.
